AU2010215275B2 - Antibodies to Clostridium difficile toxins - Google Patents

Antibodies to Clostridium difficile toxins Download PDF

Info

Publication number
AU2010215275B2
AU2010215275B2 AU2010215275A AU2010215275A AU2010215275B2 AU 2010215275 B2 AU2010215275 B2 AU 2010215275B2 AU 2010215275 A AU2010215275 A AU 2010215275A AU 2010215275 A AU2010215275 A AU 2010215275A AU 2010215275 B2 AU2010215275 B2 AU 2010215275B2
Authority
AU
Australia
Prior art keywords
toxin
difficile
antibodies
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010215275A
Other languages
English (en)
Other versions
AU2010215275A1 (en
Inventor
John Landon
Clifford Shone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Health
Micropharm Ltd
Original Assignee
Sec Dep For Health
UK Secretary of State for Health
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0902851A external-priority patent/GB0902851D0/en
Priority claimed from GB0916153A external-priority patent/GB0916153D0/en
Application filed by Sec Dep For Health, UK Secretary of State for Health, Micropharm Ltd filed Critical Sec Dep For Health
Publication of AU2010215275A1 publication Critical patent/AU2010215275A1/en
Assigned to MICROPHARM LIMITED, THE SECRETARY OF STATE FOR HEALTH reassignment MICROPHARM LIMITED Request for Assignment Assignors: HEALTH PROTECTION AGENCY, MICROPHARM LIMITED
Application granted granted Critical
Publication of AU2010215275B2 publication Critical patent/AU2010215275B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010215275A 2009-02-20 2010-02-19 Antibodies to Clostridium difficile toxins Active AU2010215275B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0902851A GB0902851D0 (en) 2009-02-20 2009-02-20 Antibodies to clostridium difficile toxins
GB0902851.5 2009-02-20
GB0916153A GB0916153D0 (en) 2009-09-15 2009-09-15 Antibodies to clostridium difficile toxins
GB0916153.0 2009-09-15
PCT/GB2010/050288 WO2010094970A1 (en) 2009-02-20 2010-02-19 Antibodies to clostridium difficile toxins

Publications (2)

Publication Number Publication Date
AU2010215275A1 AU2010215275A1 (en) 2011-07-28
AU2010215275B2 true AU2010215275B2 (en) 2016-03-31

Family

ID=42109880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010215275A Active AU2010215275B2 (en) 2009-02-20 2010-02-19 Antibodies to Clostridium difficile toxins

Country Status (7)

Country Link
US (2) US8709428B2 (https=)
EP (1) EP2405940B1 (https=)
JP (1) JP5740714B2 (https=)
CN (1) CN102365097A (https=)
AU (1) AU2010215275B2 (https=)
CA (1) CA2752815A1 (https=)
WO (1) WO2010094970A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
GB201110712D0 (en) 2011-06-23 2011-08-10 Univ Ulster Diagnostic methods
SG10201701055WA (en) * 2011-09-16 2017-03-30 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
HK1200463A1 (en) 2012-03-02 2015-08-07 瑞泽恩制药公司 Human antibodies to clostridium difficile toxins
WO2014061783A1 (ja) 2012-10-19 2014-04-24 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
EP2986316B1 (en) * 2013-04-19 2023-01-25 Immuron Limited Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
CA2910200A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
CN103665141B (zh) * 2013-12-31 2015-09-16 北京大学 与艰难梭菌细胞毒素b相互作用的蛋白
EP3126840B1 (en) * 2014-04-01 2020-05-06 Institut Pasteur Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
USD952157S1 (en) 2020-06-19 2022-05-17 Qualigen Inc. Whole blood treatment cartridge
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121422A2 (en) * 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
WO1996007430A1 (en) 1994-09-06 1996-03-14 Galagen, Inc. Therapeutic treatment of clostridium difficile associated diseases
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US20020009429A1 (en) 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
CN101363867B (zh) 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121422A2 (en) * 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REDWAN et al (2005) " Comp. Immun. Microbiol. Infect. Dis. 28: 167-176 *

Also Published As

Publication number Publication date
EP2405940A1 (en) 2012-01-18
JP5740714B2 (ja) 2015-06-24
JP2012518624A (ja) 2012-08-16
EP2405940B1 (en) 2021-08-04
WO2010094970A1 (en) 2010-08-26
US8709428B2 (en) 2014-04-29
CA2752815A1 (en) 2010-08-26
CN102365097A (zh) 2012-02-29
US20150010580A1 (en) 2015-01-08
US20120121607A1 (en) 2012-05-17
AU2010215275A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
AU2010215275B2 (en) Antibodies to Clostridium difficile toxins
CA2550108C (en) Active immunization against clostridium difficile disease
AU688763B2 (en) (Clostridial) toxin disease therapy
US8921529B2 (en) Therapies for preventing or suppressing Clostridium difficile infection
EP2625193B1 (en) Clostridium difficile antigens
EP2844283B1 (en) Clostridium difficile antigens
US5955293A (en) Assays for shiga toxin and shiga-like toxins
Hiriart et al. Preclinical studies of NEAST (neutralizing equine anti-Shiga toxin): a potential treatment for prevention of Stec-Hus
CN101570574B (zh) 一种抗I型志贺毒素IgY抗体、及其制备方法和用途
KR970001709B1 (ko) 약독화 녹농균주 cfcpa 70018을 이용한 녹농균 감염 예방 백신
KR970001708B1 (ko) 약독화 녹농균주 cfcpa 60534를 이용한 녹농균 감염 예방 백신
HK1202805B (en) Clostridium difficile antigens
HK1099198B (en) Passive immunization against clostridium difficile disease

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THE SECRETARY OF STATE FOR HEALTH; MICROPHARM LIMI

Free format text: FORMER APPLICANT(S): HEALTH PROTECTION AGENCY; MICROPHARM LIMITED

FGA Letters patent sealed or granted (standard patent)